Compare Stocks: TXG, PACB, TWST, and ILMN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ILMN Illumina	$262.54 -2.0%	$234.53	$94.00 ▼ $309.35	$39.64B	1.41	4.37 million shs	2.49 million shs
PACB Pacific Biosciences of California	$1.73 -11.7%	$1.61	$1.07 ▼ $3.44	$537.74M	2.19	20.23 million shs	10.42 million shs
TWST Twist Bioscience	$132.75 -8.1%	$148.09	$23.30 ▼ $219.71	$8.32B	2.19	3.29 million shs	2.83 million shs
TXG 10x Genomics	$69.86 -3.5%	$71.11	$11.81 ▼ $102.81	$9.10B	1.99	4.23 million shs	3.39 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ILMN Illumina	0.00%	-5.62%	+7.08%	+40.66%	+182.30%
PACB Pacific Biosciences of California	0.00%	-25.75%	+25.36%	+20.14%	-0.57%
TWST Twist Bioscience	0.00%	-16.92%	-14.66%	+41.45%	+314.33%
TXG 10x Genomics	0.00%	-13.38%	-9.24%	+59.72%	+487.55%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ILMN Illumina	$262.54 -2.0%	$234.53	$94.00 ▼ $309.35	$39.64B	1.41	4.37 million shs	2.49 million shs
PACB Pacific Biosciences of California	$1.73 -11.7%	$1.61	$1.07 ▼ $3.44	$537.74M	2.19	20.23 million shs	10.42 million shs
TWST Twist Bioscience	$132.75 -8.1%	$148.09	$23.30 ▼ $219.71	$8.32B	2.19	3.29 million shs	2.83 million shs
TXG 10x Genomics	$69.86 -3.5%	$71.11	$11.81 ▼ $102.81	$9.10B	1.99	4.23 million shs	3.39 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ILMN Illumina	0.00%	-5.62%	+7.08%	+40.66%	+182.30%
PACB Pacific Biosciences of California	0.00%	-25.75%	+25.36%	+20.14%	-0.57%
TWST Twist Bioscience	0.00%	-16.92%	-14.66%	+41.45%	+314.33%
TXG 10x Genomics	0.00%	-13.38%	-9.24%	+59.72%	+487.55%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ILMN Illumina	2.44	Hold	$225.94	-13.94% Downside
PACB Pacific Biosciences of California	1.83	Reduce	$1.71	-1.01% Downside
TWST Twist Bioscience	2.46	Hold	$143.67	8.22% Upside
TXG 10x Genomics	2.28	Hold	$68.00	-2.66% Downside

Current Analyst Ratings Breakdown

Latest TXG, PACB, TWST, and ILMN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/13/2026	PACB Pacific Biosciences of California	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/13/2026	TXG 10x Genomics	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$70.00
10/13/2026	TXG 10x Genomics	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Hold	$47.00 ➝ $70.00
10/13/2026	TWST Twist Bioscience	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$115.00 ➝ $190.00
10/13/2026	ILMN Illumina	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Hold	$210.00 ➝ $270.00
10/12/2026	TXG 10x Genomics	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Equal Weight	$40.00 ➝ $70.00
10/12/2026	TXG 10x Genomics	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$60.00 ➝ $100.00
10/12/2026	TWST Twist Bioscience	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$120.00 ➝ $205.00
10/8/2026	TWST Twist Bioscience	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Hold	$150.00
10/7/2026	TWST Twist Bioscience	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$112.00 ➝ $215.00
10/7/2026	ILMN Illumina	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Underweight	$160.00 ➝ $200.00

(Data available from 10/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ILMN Illumina	$4.49B	8.82	$6.71 per share	39.10	$17.82 per share	14.73
PACB Pacific Biosciences of California	$160.01M	3.36	$0.79 per share	2.19	$0.02 per share	86.50
TWST Twist Bioscience	$431.80M	19.28	N/A	N/A	$7.84 per share	16.93
TXG 10x Genomics	$642.82M	14.16	N/A	N/A	$6.24 per share	11.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ILMN Illumina	$850M	$5.36	48.98	42.90	3.72	18.36%	29.84%	12.17%	10/29/2026 (Estimated)
PACB Pacific Biosciences of California	-$546.38M	-$0.43	N/A	N/A	N/A	-82.49%	-5,752.12%	-19.52%	11/3/2026 (Estimated)
TWST Twist Bioscience	-$77.67M	-$2.22	N/A	N/A	N/A	-31.66%	-28.64%	-19.94%	11/13/2026 (Estimated)
TXG 10x Genomics	-$43.54M	-$0.59	N/A	N/A	N/A	-12.18%	-9.33%	-7.30%	11/5/2026 (Estimated)

Latest TXG, PACB, TWST, and ILMN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/13/2026	Q4 2026	TWST Twist Bioscience	-$0.3845	N/A	N/A	N/A	$123.59 million	N/A
11/5/2026	Q3 2026	TXG 10x Genomics	-$0.2625	N/A	N/A	N/A	$147.96 million	N/A
11/3/2026	Q3 2026	PACB Pacific Biosciences of California	-$0.1260	N/A	N/A	N/A	$43.82 million	N/A
10/29/2026	Q3 2026	ILMN Illumina	$1.36	N/A	N/A	N/A	$1.15 billion	N/A
8/6/2026	Q2 2026	TXG 10x Genomics	-$0.2431	-$0.14	+$0.1031	-$0.14	$146.67 million	$151.04 million
8/3/2026	Q2 2026	PACB Pacific Biosciences of California	-$0.1280	-$0.14	-$0.0120	-$0.14	$42.90 million	$39.01 million
8/3/2026	Q3 2026	TWST Twist Bioscience	-$0.5063	-$0.56	-$0.0538	-$0.56	$114.55 million	$118.38 million
7/30/2026	Q2 2026	ILMN Illumina	$1.23	$1.31	+$0.08	$1.35	$1.13 billion	$1.16 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ILMN Illumina	N/A	N/A	N/A	N/A	N/A
PACB Pacific Biosciences of California	N/A	N/A	N/A	N/A	N/A
TWST Twist Bioscience	N/A	N/A	N/A	N/A	N/A
TXG 10x Genomics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ILMN Illumina	0.53	1.80	1.40
PACB Pacific Biosciences of California	N/A	4.92	4.03
TWST Twist Bioscience	0.03	2.67	2.38
TXG 10x Genomics	N/A	5.69	5.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ILMN Illumina	89.42%
PACB Pacific Biosciences of California	N/A
TWST Twist Bioscience	N/A
TXG 10x Genomics	84.68%

Insider Ownership

Company	Insider Ownership
ILMN Illumina	2.90%
PACB Pacific Biosciences of California	3.70%
TWST Twist Bioscience	3.08%
TXG 10x Genomics	8.84%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ILMN Illumina	8,650	151.00 million	146.62 million	Optionable
PACB Pacific Biosciences of California	485	310.83 million	299.33 million	Optionable
TWST Twist Bioscience	979	62.71 million	60.78 million	Optionable
TXG 10x Genomics	1,178	130.29 million	118.77 million	Optionable

TXG, PACB, TWST, and ILMN Headlines

Recent News About These Companies

Counterpoint Mutual Funds LLC Acquires New Stake in 10x Genomics $TXG

3 hours ago | marketbeat.com

A Look at 10x Genomics Inc (TXG) After 3.5% Decline -- GF Value $18.31 vs Price $69.86

October 16 at 8:00 PM | gurufocus.com

10x Genomics (TXG) Stock Fair Value Rises After Analysts Back AI And Atera Demand

October 16 at 11:48 AM | finance.yahoo.com

10x Genomics, Inc. (TXG) Stock Analysis: Navigating Opportunities Amidst a Complex Valuation Landscape

October 13, 2026 | directorstalkinterviews.com

10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026

October 13, 2026 | prnewswire.com

Biotech stock plummeted at the $100 milestone. Two-thirds of the week's losses occurred in a single night for one stock [Investment Record #63]

October 12, 2026 | note.comN

10x Genomics (NASDAQ:TXG) Shares Down 7.1% - Time to Sell?

October 12, 2026 | marketbeat.com

10x Genomics (NASDAQ:TXG) Stock Now Rated "Hold" by Sell-Side Analysts

October 12, 2026 | americanbankingnews.com

10x Genomics (NASDAQ:TXG) Stock Has Average Price Target of $58.60

October 12, 2026 | marketbeat.com

10x Genomics $TXG Holdings Decreased by Mirador Capital Partners LP

October 10, 2026 | marketbeat.com

Why are 10x Genomics (TXG) shares soaring today

October 9, 2026 | msn.com

10x Genomics (NASDAQ:TXG) Shares Climb 9.2% - Still a Buy?

October 9, 2026 | marketbeat.com

Is 10x Genomics (TXG) Using Its Fred Hutch Oncology Alliance To Redefine Its Clinical Moat?

October 9, 2026 | finance.yahoo.com

10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research

October 8, 2026 | zacks.com

10x Genomics Enters Research Collaboration With Fred Hutchinson Cancer Center

October 8, 2026 | finance.yahoo.com

10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers

October 7, 2026 | prnewswire.com

10x Genomics (NASDAQ:TXG) Stock Falls 6.2% - Here's Why

October 6, 2026 | marketbeat.com

10x Genomics Slides as Rally Cools After Recent Product-Launch Surge

October 6, 2026 | quiverquant.comQ

10x Genomics (TXG) Starts Atera Shipments And Sentira, Is The Upside Already Priced In?

October 5, 2026 | finance.yahoo.com

10x Genomics (NASDAQ:TXG) Reaches New 52-Week High - What's Next?

October 5, 2026 | marketbeat.com

10x Genomics consensus price target raised 12.04% to MX$958.28

October 3, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXG, PACB, TWST, and ILMN Company Descriptions

Illumina NASDAQ:ILMN

$262.54 -5.39 (-2.01%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$261.05 -1.49 (-0.57%)

As of 10/16/2026 07:56 PM Eastern

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Pacific Biosciences of California NASDAQ:PACB

$1.73 -0.23 (-11.73%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$1.76 +0.02 (+1.45%)

As of 10/16/2026 07:56 PM Eastern

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Twist Bioscience NASDAQ:TWST

$132.75 -11.74 (-8.13%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$131.30 -1.45 (-1.09%)

As of 10/16/2026 07:58 PM Eastern

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

10x Genomics NASDAQ:TXG

$69.86 -2.53 (-3.49%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$69.56 -0.30 (-0.43%)

As of 10/16/2026 07:34 PM Eastern

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TXG, PACB, TWST, and ILMN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TXG, PACB, TWST, and ILMN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TXG, PACB, TWST, and ILMN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXG, PACB, TWST, and ILMN Company Descriptions

Illumina NASDAQ:ILMN

Pacific Biosciences of California NASDAQ:PACB

Twist Bioscience NASDAQ:TWST

10x Genomics NASDAQ:TXG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TXG, PACB, TWST, and ILMN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TXG, PACB, TWST, and ILMN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TXG, PACB, TWST, and ILMN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXG, PACB, TWST, and ILMN Company Descriptions

Illumina NASDAQ:ILMN

Pacific Biosciences of California NASDAQ:PACB

Twist Bioscience NASDAQ:TWST

10x Genomics NASDAQ:TXG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools